Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026)
Galectin Therapeutics' quarterly Net Income towards Common Stockholders came in at -$5.1 million in Q1 2026, up 47.25% year-on-year from -$3.4 million in Q1 2025, and up 8.9% quarter-over-quarter from -$5.6 million in Q4 2025.
Galectin Therapeutics has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$5.1 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 47.25% year-over-year to -$5.1 million; the trailing twelve-month figure through Mar 2026 stood at -$26.4 million (up 41.65% YoY), and the FY2025 full-year result was -$31.0 million, up 34.38% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.1 million, up from -$5.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$5.1 million in Q1 2026, with the low at -$14.0 million in Q3 2023.
- Average Net Income towards Common Stockholders over 5 years is -$9.8 million, with a median of -$9.9 million recorded in 2022.
- Year-over-year, Net Income towards Common Stockholders sank 63.63% in 2023 and jumped 53.77% in 2025.
- Tracing GALT's Net Income towards Common Stockholders over 5 years: stood at -$10.7 million in 2022, then rose by 5.97% to -$10.1 million in 2023, then retreated by 19.58% to -$12.0 million in 2024, then jumped by 53.77% to -$5.6 million in 2025, then grew by 8.9% to -$5.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.1 million (Q1 2026), -$5.6 million (Q4 2025), and -$8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -5.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.07 Mn |
| Dec 31, 2025 | -5.56 Mn |
| Sep 30, 2025 | -8.22 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -12.03 Mn |
| Sep 30, 2024 | -11.24 Mn |
| Jun 30, 2024 | -12.44 Mn |
| Mar 31, 2024 | -11.50 Mn |
| Dec 31, 2023 | -10.06 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -9.18 Mn |
| Mar 31, 2023 | -11.53 Mn |
| Dec 31, 2022 | -10.70 Mn |
| Sep 30, 2022 | -8.58 Mn |
| Jun 30, 2022 | -9.68 Mn |
| Mar 31, 2022 | -9.92 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.56 Mn |
| Jun 30, 2021 | -8.51 Mn |
| Mar 31, 2021 | -6.34 Mn |
| Dec 31, 2020 | -7.92 Mn |
| Sep 30, 2020 | -5.96 Mn |
| Jun 30, 2020 | -6.18 Mn |
| Mar 31, 2020 | -3.55 Mn |
| Dec 31, 2019 | -5.20 Mn |
| Sep 30, 2019 | -2.82 Mn |
| Jun 30, 2019 | -3.07 Mn |
| Mar 31, 2019 | -9.09 Mn |
| Dec 31, 2018 | -3.35 Mn |
| Sep 30, 2018 | -3.05 Mn |
| Jun 30, 2018 | -4.11 Mn |
| Mar 31, 2018 | -4.54 Mn |
| Dec 31, 2017 | -2.79 Mn |
| Sep 30, 2017 | -4.66 Mn |
| Jun 30, 2017 | -4.81 Mn |
| Mar 31, 2017 | -5.21 Mn |
| Dec 31, 2016 | -4.87 Mn |
| Sep 30, 2016 | -4.65 Mn |
| Jun 30, 2016 | -5.83 Mn |
| Mar 31, 2016 | -7.01 Mn |
| Dec 31, 2015 | -4.97 Mn |
| Sep 30, 2015 | -6.15 Mn |
| Jun 30, 2015 | -4.93 Mn |
| Mar 31, 2015 | -5.07 Mn |
| Dec 31, 2014 | -3.97 Mn |
| Sep 30, 2014 | -3.85 Mn |
| Jun 30, 2014 | -3.73 Mn |
| Mar 31, 2014 | -5.41 Mn |
| Dec 31, 2013 | -3.11 Mn |
| Sep 30, 2013 | -3.72 Mn |
| Jun 30, 2013 | -11.64 Mn |
| Mar 31, 2013 | -3.47 Mn |
| Dec 31, 2012 | -2.71 Mn |
| Sep 30, 2012 | -2.99 Mn |
| Jun 30, 2012 | -2.98 Mn |
| Mar 31, 2012 | -2.20 Mn |
| Dec 31, 2011 | -3.72 Mn |
| Sep 30, 2011 | -2.34 Mn |
| Jun 30, 2011 | -3.93 Mn |
| Mar 31, 2011 | -2.72 Mn |
| Dec 31, 2010 | -1.52 Mn |
| Sep 30, 2010 | -1.90 Mn |
| Jun 30, 2010 | -2.48 Mn |